

## PRESS RELEASE

Date 7 May 2015  
Contact Investor Relations: Julien Vignot, Head Investor Relations, Galenica Group  
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group

Subject 2015 Annual General Meeting of Galenica Ltd.

### **87<sup>th</sup> Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors**

**For the first time, shareholders had a prospective vote on the maximum possible total remuneration of the Board of Directors, the Executive Chairman and the Corporate Executive Committee for 2016. Two new members were also proposed for election to the Board of Directors: Marc de Garidel, Chairman of the Board of Directors and CEO of Ipsen, France, as well as Romeo Cerutti, member of the Executive Board and General Counsel of Credit Suisse Group Ltd., Switzerland. The shareholders approved all the proposals put forward by the Board of Directors.**

The 87<sup>th</sup> Annual General Meeting of Galenica Ltd. in Bern was attended by 370 shareholders, representing a total of 58% of the registered voting shares of Galenica Ltd.

The shareholders voted in favour of the proposals put forward by the Board of Directors on all items on the agenda:

The Annual General Meeting approved the Annual Report and the 2014 Annual Financial Statements of Galenica Ltd. as well as the Consolidated Financial Statements of the Galenica Group for 2014 and discharged the members of the Board of Directors and the Corporate Executive Committee from liability for their activities in 2014.

The Remuneration Report was submitted to shareholders for a consultative vote for the eighth time.

The 2014 Remuneration Report was approved by more than 91% of the shareholders.

Also approved was the dividend of CHF 15.00 (+7.1%, prior year: CHF 14.00) proposed by the Board of Directors, which will be paid to shareholders on 15 May 2015.

#### **Total remuneration for financial year 2016**

A prospective vote on the maximum possible remuneration of the Board of Directors and Corporate Executive Committee for the following year was held for the first time at the Annual General Meeting 2015. In addition, the new contract with the Executive Chairman for the period 2017 until the 2020 Annual General Meeting has been presented to the shareholders.

Shareholders approved the proposed maximum total remuneration of the Board of Directors and the Executive Chairman by more than 92% as well as of the Corporate Executive Committee by approximately 97% for 2016. This remuneration is comparable to those of previous years.

#### **Elections**

The following two new members were elected to the Board of Directors for a term of office lasting one year: Marc de Garidel, Chairman of the Board of Directors and CEO of Ipsen, France, as well as Dr. Romeo Cerutti, member of the Executive Board and General Counsel of Credit Suisse Group Ltd., Switzerland.

**Re-elections to the Board of Directors:** All existing members of the Board of Directors were re-elected for a term of office lasting one year: Etienne Jornod as Executive Chairman, and as members of the Board of Directors: This E. Schneider (Vice Chairman), Daniela Bosshardt-Hengartner, Prof. Dr. Michel Burnier, Dr. Hans Peter Frick, Dr. Sylvie Grégoire, Fritz Hirsbrunner and Stefano Pessina.

Date 7 May 2015  
Page 2/2  
Subject 2015 Annual General Meeting of Galenica Ltd.

**Re-elections to the Remuneration Committee:** The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of office lasting one year: Daniela Bosshardt-Hengartner, Prof. Dr. Michel Burnier and This E. Schneider. Following the Annual General Meeting, the Board of Directors appointed Daniela Bosshardt-Hengartner as Chairwoman of the Remuneration Committee.

**Important dates:**

Half-year report	11 August 2015
Annual General Meeting 2016	28 April 2016

**For further information, please contact:**

**Media Relations:**

Christina Hertig, Head Corporate Communications  
Tel. +41 58 852 85 17  
E-mail: [media@galenica.com](mailto:media@galenica.com)

**Investor Relations:**

Julien Vignot, Head Investor Relations  
Tel. +41 58 852 85 29  
E-mail: [investors@galenica.com](mailto:investors@galenica.com)

***Galenica** is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).*

*For more information, please visit the company's website at [www.galenica.com](http://www.galenica.com).*